Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance.
Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance.
复制标题
DOI：
10.1038/bjc.1997.5
复制
发表时间：
1997
影响因子：
8.8
通讯作者：
Johnston CL
中科院分区：
文献类型：
--
作者：
Yiangou C;Gomm JJ;Coope RC;Law M;Luqmani YA;Shousha S;Coombes RC;Johnston CL
本文检测成纤维细胞生长因子-2(FGF2)在人乳腺恶性病变中的表达。采用半定量逆转录聚合酶链式反应(RT-PCR)对51例患者进行了一系列临床随访，平均随访84个月(Luqmani等，1992)。免疫组织化学和Western blotting结果显示，乳腺组织中成纤维细胞生长因子-2的表达水平与成纤维细胞生长因子-2基因的表达水平呈正相关。成纤维细胞生长因子-2在恶性和非恶性乳腺组织中均有表达，但三种方法在恶性组织中的表达均较少。乳腺组织冰冻切片免疫组织化学染色显示，成纤维细胞生长因子-2在肌上皮细胞和非恶性上皮细胞中均有表达，而在恶性上皮细胞中的表达一般较低或检测不到。免疫组织化学检测结果与RT-PCR检测结果具有很好的相关性，表明成纤维细胞生长因子-2和成纤维细胞生长因子-2在样本中的表达水平相似。未发现成纤维细胞生长因子-2mRNA的表达与T分期、淋巴结状态或雌激素受体状态相关。然而，Kaplan-Meier生存图显示，较高水平的成纤维细胞生长因子-2与改善总体和无病生存率有关。我们认为，成纤维细胞生长因子-2的表达可能是乳腺癌预后的一个有价值的指标。
This paper examines the expression of fibroblast growth factor 2 (FGF-2) in the malignant human breast. Semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to assess the level of expression of FGF-2 in a series of 51 patients clinically followed up for a median of 84 months (Luqmani et al, 1992). Immunohistochemistry and Western blotting were used to show that the level of FGF-2 in breast tissues correlated with the amount of FGF-2 mRNA. FGF-2 was present in both malignant and non-malignant breast, although less was expressed in malignant tissues as determined by all three methods. Immunohistochemistry on frozen sections of breast tissue showed expression of FGF-2 in myoepithelial and epithelial cells in non-malignant samples and generally lower or undetectable levels of staining in malignant epithelial cells. The results obtained by immunohistochemistry correlated well with RT-PCR data showing similar levels of FGF-2 and FGF-2 mRNA expression in samples. No correlation was found between FGF-2 mRNA expression and T stage, nodal status or oestrogen receptor status. However, Kaplan-Meier survival plots show that higher levels of FGF-2 are associated with improved overall and disease-free survival. We suggest that FGF-2 expression may have value as a prognostic indicator in breast cancer.